![Alf Gunnar Martin Nicklasson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alf Gunnar Martin Nicklasson
Président chez
ZEALAND PHARMA A/S
Fortune : 1 M $ au 31/05/2026
Profil
Alf Gunnar Martin Nicklasson is currently Chairman at Zealand Pharma A since 2015, Non-Executive Chairman at Kymab Ltd. since 2017, Independent Non-Executive Director at Basilea Pharmaceutica AG since 2016, Director at BioCrine AB, Stockholm Chamber of Commerce, and Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt, Member of the Royal Swedish Academy of Engineering Sciences, The Royal Bachelors' Club, and Swedish Academy For Pharmaceutical Sciences, Senior Partner at Nicklasson Life Science AB since 2011, and Honorary Associate Professor at the University of Uppsala.
Former positions include Chief Executive Officer at AstraZeneca AB from 1991 to 2007, President & Chief Executive Officer at Biovitrum AB from 2007 to 2010, Chief Executive Officer at Swedish Orphan International Holding AB from 2007 to 2010, President & Chief Executive Officer at Swedish Orphan Biovitrum AB from 2007 to 2010, Chairman at Orexo AB from 2012 to 2020, Chairman at Kymab Group Ltd. from 2017 to 2021, Chairman at Nykode Therapeutics ASA from 2021 to 2025, Independent Director at POZEN, Inc. from 2011 to 2014, Independent Director at BioInvent International AB from 2016 to 2017, EVP-Product Strategy & Business Development at AstraZeneca PLC from 1999 to 2007, and other director and chairman roles at various firms.
Education includes graduate and doctorate degrees from the University of Uppsala.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ZEALAND PHARMA A/S 0,03% | 31/12/2025 | 23 626 ( 0,03% ) | 1 M $ | 31/05/2026 |
| 31/12/2025 | 2 745 ( 0,02% ) | 183 035 $ | 31/05/2026 | |
| 31/12/2024 | 142 000 ( 0,04% ) | 48 203 $ | 31/05/2026 |
Postes actifs de Alf Gunnar Martin Nicklasson
| Sociétés | Poste | Début |
|---|---|---|
| BASILEA PHARMACEUTICA AG | Directeur/Membre du Conseil | 21/04/2016 |
| ZEALAND PHARMA A/S | Président | - |
Swedish Academy For Pharmaceutical Sciences | Corporate Officer/Principal | - |
The Royal Bachelors' Club | Corporate Officer/Principal | - |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops human monoclonal antibody drugs | Président | 16/06/2017 |
Stockholm Chamber of Commerce
 Stockholm Chamber of Commerce Miscellaneous Commercial ServicesCommercial Services Chamber of Commerce | Directeur/Membre du Conseil | - |
Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt
 Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt Miscellaneous Commercial ServicesCommercial Services Operates as a heart and lung foundation | Directeur/Membre du Conseil | - |
Royal Swedish Academy of Engineering Sciences
 Royal Swedish Academy of Engineering Sciences Miscellaneous Commercial ServicesCommercial Services Operates engineering science academy | Corporate Officer/Principal | - |
BioCrine AB | Directeur/Membre du Conseil | - |
| ░░░░░░░░░░ ░░░░ ░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Alf Gunnar Martin Nicklasson
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░ ░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░ ░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Alf Gunnar Martin Nicklasson
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
73
Relations au 1er degré
31
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 31 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
POZEN, Inc.
 POZEN, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops therapeutics for diseases | Health Technology |
Premier Research Group Ltd.
 Premier Research Group Ltd. Miscellaneous Commercial ServicesCommercial Services Provides contract research services to pharmaceutical industry | Commercial Services |
EffRx Pharmaceuticals SA
 EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology Develops and markets drugs specializing in musculoskeletal & rare diseases | Health Technology |
BioInvent International AB
 BioInvent International AB BiotechnologyHealth Technology Develops and manufactures immunomodulatory antibodies for cancer treatment | Health Technology |
AstraZeneca AB
 AstraZeneca AB Miscellaneous Commercial ServicesCommercial Services Researches and develops pharmaceutical products | Commercial Services |
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Develops pharmaceuticals and conducts medical research services | Commercial Services |
Orexo AB
 Orexo AB Pharmaceuticals: MajorHealth Technology Manufactures and commercializes pharmaceutical products | Health Technology |
Swedish Orphan International Holding AB
 Swedish Orphan International Holding AB Pharmaceuticals: MajorHealth Technology Develops, manufactures and sells pharmaceutical products and drugs | Health Technology |
Basilea Pharmaceutica AG
 Basilea Pharmaceutica AG Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
University of Uppsala
 University of Uppsala Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Zealand Pharma A/S
 Zealand Pharma A/S BiotechnologyHealth Technology Operates as a biotechnology company that discovers and develops peptide based medicines | Health Technology |
Vivesto AB
 Vivesto AB Pharmaceuticals: GenericHealth Technology Develops cancer drugs based on nanotechnology for human and veterinary use | Health Technology |
BioCrine AB | |
Royal Swedish Academy of Engineering Sciences
Royal Swedish Academy of Engineering Sciences Miscellaneous Commercial ServicesCommercial Services Operates engineering science academy | Commercial Services |
Denator AB
 Denator AB Medical SpecialtiesHealth Technology Provides instruments and consumables that stabilize biological samples | Health Technology |
Nykode Therapeutics ASA
 Nykode Therapeutics ASA Pharmaceuticals: MajorHealth Technology Develops vaccines and immunotherapy against infectious diseases and cancer | Health Technology |
Astra Hässle AB | |
Sanivo Pharma AS
 Sanivo Pharma AS Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products and services | Health Technology |
Stockholm Chamber of Commerce
Stockholm Chamber of Commerce Miscellaneous Commercial ServicesCommercial Services Chamber of Commerce | Commercial Services |
Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt
Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt Miscellaneous Commercial ServicesCommercial Services Operates as a heart and lung foundation | Commercial Services |
Swedish Orphan Biovitrum AB
 Swedish Orphan Biovitrum AB Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceuticals and orphan drugs in the areas of hematology, immunology and specialty care | Health Technology |
Egetis Therapeutics AB
 Egetis Therapeutics AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
The Royal Bachelors' Club | |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops human monoclonal antibody drugs | Health Technology |
Swedish Academy For Pharmaceutical Sciences | |
Nicklasson Life Science AB | |
Farma Investment AS
 Farma Investment AS Real Estate Investment TrustsFinance Invests in real estate properties | Finance |
Astra Pain Control AB | |
IRLAB Therapeutics AB
 IRLAB Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products for neurological diseases | Health Technology |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops human monoclonal antibody drugs | Health Technology |
Choisissez Zonebourse 
